2. Search Result
Search Result
Results for "

glucose transport

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dyes

1

Biochemical Assay Reagents

1

Peptides

16

Natural
Products

3

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0133
    Natamycin
    Maximum Cited Publications
    8 Publications Verification

    Pimaricin

    		 Environmental Pollutants Antibiotic Endogenous Metabolite Fungal Bacterial Infection
    Natamycin (Pimaricin) is a macrolide antibiotic agent produced by several Streptomyces strains. Natamycin inhibits the growth of fungi via inhibition of amino acid and glucose transport across the plasma membrane. Natamycin is a food preservative, an antifungal agent in agriculture, and is widely used for fungal keratitis research .
    Natamycin
  • HY-N2024
    Maltose
    1 Publications Verification

    		 Endogenous Metabolite Glycosidase Metabolic Disease
    Maltose is a disaccharide composed of two glucose molecules linked together. Maltose is an endogenous metabolic product in plants, yeast, or bacteria, and it participates in carbon source storage and metabolism. Maltose is a key core metabolite and main transport form in the temporary starch degradation, carbon output, and subsequent sucrose synthesis metabolism of the night chloroplast. In X. dendrorhous, maltose can act as a sugar donor and is converted into isomaltulose by α-glucosidase). Maltose can act as a osmotic agent, supporting continuous capillary ultrafiltration and preventing severe metabolic disorders .
    Maltose
  • HY-145597
    KL-11743
    5 Publications Verification

    		 GLUT Disulfidptosis Metabolic Disease Cancer
    KL-11743 is a potent, orally active, and glucose-competitive inhibitor of the class I glucose transporters, with IC50s of 115, 137, 90, and 68 nM for GLUT1, GLUT2, GLUT3, and GLUT4, respectively. KL-11743 specifically blocks glucose metabolism. KL-11743 can synergize with electron transport inhibitors to induce cell death. In addition, KL-11743 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .
    KL-11743
  • HY-161834
    RG100204
    1 Publications Verification

    		 Pyroptosis Aquaporin NOD-like Receptor (NLR) p38 MAPK Infection Metabolic Disease Inflammation/Immunology
    RG100204 is a selective, orally available inhibitor of the aquaporin AQP9. RG100204 directly inhibits AQP9 channel function, preventing the transmembrane transport of water, glycerol, and H 2O 2. RG100204 reduces the activation of the NLRP3 inflammasome and p38 MAPK signaling pathways, thereby alleviating inflammation and pyroptosis. RG100204 reduces multi-organ dysfunction in a mouse sepsis model and shows glucose-regulating effects in diabetic db/db mice .
    RG100204
  • HY-N0668
    Rubusoside
    2 Publications Verification

    		 GLUT Amylases NF-κB Metabolic Disease Inflammation/Immunology Cancer
    Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .
    Rubusoside
  • HY-N2024A
    Maltose monohydrate
    1 Publications Verification

    		 Endogenous Metabolite Glycosidase Metabolic Disease
    Maltose monohydrate is a disaccharide composed of two glucose molecules linked together. Maltose monohydrate is an endogenous metabolic product in plants, yeast, or bacteria, and it participates in carbon source storage and metabolism. Maltose monohydrate is a key core metabolite and main transport form in the temporary starch degradation, carbon output, and subsequent sucrose synthesis metabolism of the night chloroplast. In X. dendrorhous, maltose can act as a sugar donor and is converted into isomaltulose by α-glucosidase. Maltose monohydrate can act as a osmotic agent, supporting continuous capillary ultrafiltration and preventing severe metabolic disorders .
    Maltose monohydrate
  • HY-A0080
    Aminohippurate sodium
    4 Publications Verification

    Sodium p-aminohippurate; p-Aminohippuric acid sodium salt

    		 Biochemical Assay Reagents
    Aminohippurate sodium is a renal tubular transport inhibitor and a substrate for organic anion transporters. Aminohippurate sodium inhibits renal tubular reabsorption of phosphate and promotes increased urinary phosphate excretion. Aminohippurate sodium inhibits renal tubular reabsorption of vitamin C as well as the transport of glucose .
    Aminohippurate sodium
  • HY-148983
    Hydroxylamine (50% w/w in water)
    1 Publications Verification

    		 Monoamine Oxidase Bacterial GLUT Infection Metabolic Disease Inflammation/Immunology
    Hydroxylamine (50% w/w in water) is an inorganic highly reactive compound and antibacterial agent. Hydroxylamine (50% w/w in water) acutely activates the transport activity of GLUT1, inhibits Monoamine oxidase activity. Hydroxylamine (50% w/w in water) inhibits nitrite oxidizing bacteria. Hydroxylamine (50% w/w in water) activates glucose uptake. Hydroxylamine (50% w/w in water) can be used in the research of inflammatory diseases and allergies[1][2][3][4] .
    Hydroxylamine (50% w/w in water)
  • HY-N0468
    Rebaudioside D
    1 Publications Verification

    		 FXR Acetyl-CoA Carboxylase Metabolic Disease
    Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D
  • HY-N2024AS1
    Maltose-13C12 monohydrate

    		Isotope-Labeled Compounds Endogenous Metabolite Glycosidase Metabolic Disease
    Maltose monohydrate- 13C12 is the 13C labeled isotope of Maltose monohydrate. Maltose monohydrate is a disaccharide composed of two glucose molecules linked together. Maltose monohydrate is an endogenous metabolic product in plants, yeast, or bacteria, and it participates in carbon source storage and metabolism. Maltose monohydrate is a key core metabolite and main transport form in the temporary starch degradation, carbon output, and subsequent sucrose synthesis metabolism of the night chloroplast. In X. dendrorhous, maltose can act as a sugar donor and is converted into isomaltulose by α-glucosidase. Maltose monohydrate can act as a osmotic agent, supporting continuous capillary ultrafiltration and preventing severe metabolic disorders.
    Maltose-13C12 monohydrate
  • HY-N9459
    2-Amino-2-deoxyglucose hydrochloride

    D-Glucosamine Hydrochloride

    		 GLUT Infection Neurological Disease Cancer
    2-Amino-2-deoxyglucose hydrochloride (D-Glucosamine Hydrochloride) is a glucose analog that is specifically recognized and transported by the cell membrane GLUT1. 2-Amino-2-deoxyglucose hydrochloride acts as a tumor-targeting ligand and a guiding molecule for the synthesis of prodrug conjugates, thus delivering drugs precisely to tumor cells. 2-Amino-2-deoxyglucose hydrochloride is applicable to diagnostic imaging and therapeutic efficacy monitoring of solid tumors and various cancers (e.g., breast cancer, glioblastoma). 2-Amino-2-deoxyglucose hydrochloride also helps bacteria resist lysozyme digestion by integrating into the non-N-acetylated residues of Streptococcus pneumoniae peptidoglycan. 2-Amino-2-deoxyglucose hydrochloride is used in studies on tumor metabolism and the exploration of bacterial drug resistance mechanisms .
    2-Amino-2-deoxyglucose hydrochloride
  • HY-101849
    Fasentin
    4 Publications Verification

    		 GLUT TNF Receptor Apoptosis Cardiovascular Disease Cancer
    Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .
    Fasentin
  • HY-19995
    GSK137647A
    1 Publications Verification

    GSK 137647

    		 Free Fatty Acid Receptor Metabolic Disease
    GSK137647A (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC50 values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC50 values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. GSK137647A has anti-inflammatory activity. GSK137647A induces insulin secretion and inhibits epithelial ion transport, GSK137647A is related to regulation of glucose homeostasis and anti-inflammatory response .
    GSK137647A
  • HY-113870
    6-NBDG

    		Fluorescent Dye Others
    6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .
    6-NBDG
  • HY-120103
    PF-06649298
    1 Publications Verification

    		 Sodium Channel Metabolic Disease
    PF-06649298 is a sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor. PF-06649298 specifically interacts with NaCT with an IC50 value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism .
    PF-06649298
  • HY-N7433
    4,6-O-Ethylidene-α-D-glucose

    Ethylidene-glucose

    		 GLUT Endogenous Metabolite Metabolic Disease
    4,6-O-ethylidene-α-D-glucose (Ethylidene-glucose), a glucose derivative, is a competitive exofacial binding-site inhibitor on glucose transporter 1 (GLUT1) with a Ki of 12 mM for wild-type 2-deoxy-D-glucose transport .
    4,6-O-Ethylidene-α-D-glucose
  • HY-N9429
    6-Deoxy-D-glucose

    		Others Metabolic Disease
    6-Deoxy-D-glucose is an inhibitor of glucose oxidation. 6-Deoxy-D-glucose is a structural homomorph of D-glucose, and can be used for study of D-glucose transport .
    6-Deoxy-D-glucose
  • HY-N2024R
    Maltose (Standard)

    		Reference Standards Endogenous Metabolite Glycosidase Metabolic Disease
    Maltose (Standard) is the analytical standard of Maltose. This product is intended for research and analytical applications. Maltose is a disaccharide composed of two glucose molecules linked together. Maltose is an endogenous metabolic product in plants, yeast, or bacteria, and it participates in carbon source storage and metabolism. Maltose is a key core metabolite and main transport form in the temporary starch degradation, carbon output, and subsequent sucrose synthesis metabolism of the night chloroplast. In X. dendrorhous, maltose can act as a sugar donor and is converted into isomaltulose by α-glucosidase (α-Glucosidase). Maltose can act as a osmotic agent, supporting continuous capillary ultrafiltration and preventing severe metabolic disorders.
    Maltose (Standard)
  • HY-B0133R
    Natamycin (Standard)

    Pimaricin (Standard)

    		 Reference Standards Fungal Endogenous Metabolite Antibiotic Bacterial Infection
    Natamycin (Standard) is the analytical standard of Natamycin. This product is intended for research and analytical applications. Natamycin (Pimaricin) is a macrolide antibiotic agent produced by several Streptomyces strains. Natamycin inhibits the growth of fungi via inhibition of amino acid and glucose transport across the plasma membrane. Natamycin is a food preservative, an antifungal agent in agriculture, and is widely used for fungal keratitis research .
    Natamycin (Standard)
  • HY-N2024AS
    Maltose monohydrate-d14

    		Isotope-Labeled Compounds Endogenous Metabolite Glycosidase Metabolic Disease
    Maltose monohydrate-d14 is the deuterium labeled Maltose monohydrate. Maltose monohydrate is a disaccharide composed of two glucose molecules linked together. Maltose monohydrate is an endogenous metabolic product in plants, yeast, or bacteria, and it participates in carbon source storage and metabolism. Maltose monohydrate is a key core metabolite and main transport form in the temporary starch degradation, carbon output, and subsequent sucrose synthesis metabolism of the night chloroplast. In X. dendrorhous, maltose can act as a sugar donor and is converted into isomaltulose by α-glucosidase. Maltose monohydrate can act as a osmotic agent, supporting continuous capillary ultrafiltration and preventing severe metabolic disorders.
    Maltose monohydrate-d14
  • HY-N2024B
    Maltose solution, 20% in H2O

    		Endogenous Metabolite Glycosidase Metabolic Disease
    Maltose solution, 20% in H2O is a 20% aqueous maltose solution. Maltose is a disaccharide composed of two glucose molecules linked together. Maltose is an endogenous metabolic product in plants, yeast, or bacteria, and it participates in carbon source storage and metabolism. Maltose is a key core metabolite and main transport form in the temporary starch degradation, carbon output, and subsequent sucrose synthesis metabolism of the night chloroplast. In X. dendrorhous, maltose can act as a sugar donor and is converted into isomaltulose by α-glucosidase. Maltose can act as a osmotic agent, supporting continuous capillary ultrafiltration and preventing severe metabolic disorders .
    Maltose solution, 20% in H2O
  • HY-N7430
    3-O-Methylellagic acid

    		Bacterial Infection Inflammation/Immunology
    3-O-Methylellagic acid is a nature product that can be isolated from Myrciaria cauliflora, with anti-inflammatory activity. 3-O-Methylellagic acid shows an inhibitory effect on glucose transport assay. 3-O-Methylellagic acid has antibacterial activity, with a MIC of 32 μg/mL for Staph. Aureus ATCC 25923 .
    3-O-Methylellagic acid
  • HY-142444
    SSAO/VAP-1 inhibitor 1

    		VAP-1 Metabolic Disease
    SSAO/VAP-1 inhibitor 1 is a potent inhibitor of SSAO/VAP-1. SSAO/VAP-1 promotes the transfer of Glucose transport 4 (GLUT 4) from adipocytes to the cell membrane, thereby regulating glucose transport. In endothelial cells, SSAO/VAP-1 can mediate the adhesion and exudation of leukocytes and endothelial cells, and participate in inflammatory responses. SSAO/VAP-1 inhibitor 1 has the potential for the research of inflammation and/or inflammation-related disease or diabetes and/or diabetes-related disease (extracted from patent WO2021102774A1, compound E3) .
    SSAO/VAP-1 inhibitor 1
  • HY-W037817
    Dimethyl L-glutamate

    Dimethyl glutamate

    		 Potassium Channel Bacterial Infection Metabolic Disease
    Dimethyl L-glutamate (Dimethyl glutamate), a membrane-permeable analog of Glutamate, can stimulate insulin release induced by Glucose. Dimethyl L-glutamate suppresses the KATP channel activities. Dimethyl L-glutamate inhibits E. gracilis growth and causes abnormal cell division. Dimethyl L-glutamate can be used in the research of diabetes, glucose transport, phosphorylation, and further metabolism .
    Dimethyl L-glutamate
  • HY-N2024AR
    Maltose monohydrate (Standard)

    		Reference Standards Endogenous Metabolite Glycosidase Metabolic Disease
    Maltose monohydrate (Standard) is the analytical standard of Maltose monohydrate. This product is intended for research and analytical applications. Maltose monohydrate is a disaccharide composed of two glucose molecules linked together. Maltose monohydrate is an endogenous metabolic product in plants, yeast, or bacteria, and it participates in carbon source storage and metabolism. Maltose monohydrate is a key core metabolite and main transport form in the temporary starch degradation, carbon output, and subsequent sucrose synthesis metabolism of the night chloroplast. In X. dendrorhous, maltose can act as a sugar donor and is converted into isomaltulose by α-glucosidase. Maltose monohydrate can act as a osmotic agent, supporting continuous capillary ultrafiltration and preventing severe metabolic disorders.
    Maltose monohydrate (Standard)
  • HY-N0668R
    Rubusoside (Standard)

    		GLUT Amylases NF-κB Reference Standards Metabolic Disease Inflammation/Immunology Cancer
    Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .
    Rubusoside (Standard)
  • HY-122473
    fluoro-Dapagliflozin

    		SGLT Metabolic Disease
    fluoro-Dapagliflozin, a structural analog of Dapagliflozin, is a selective SGLT2 inhibitor with Ki values of 5.3 nM and 330 nM for SGLT2 and SGLT1, respectively. fluoro-Dapagliflozin blocks glucose transport and glucose-coupled currents .
    fluoro-Dapagliflozin
  • HY-N0468R
    Rebaudioside D (Standard)

    		Reference Standards Acetyl-CoA Carboxylase FXR Metabolic Disease
    Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D (Standard)
  • HY-128424
    4'-Deoxyphlorizin

    		GLUT Metabolic Disease
    4'-Deoxyphlorizin is an inhibitor of the glucose transport system. 4'-Deoxyphlorizi has good phlorizin hydrolase inhibitory activity with the Km value of 0.59 nM and the Ki value of 0.33 nM, respectively .
    4'-Deoxyphlorizin
  • HY-N7433R
    4,6-O-Ethylidene-α-D-glucose (Standard)

    Ethylidene-glucose (Standard)

    		 Reference Standards GLUT Endogenous Metabolite Metabolic Disease
    4,6-O-ethylidene-α-D-glucose (Ethylidene-glucose), a glucose derivative, is a competitive exofacial binding-site inhibitor on glucose transporter 1 (GLUT1) with a Ki of 12 mM for wild-type 2-deoxy-D-glucose transport .
    4,6-O-Ethylidene-α-D-glucose (Standard)
  • HY-137934
    Deacetylforskolin

    7-Deacetylforskolin

    		 Endogenous Metabolite Cardiovascular Disease
    Deacetylforskolin is a deacetylated derivative of forskolin (HY-15371) that can be extracted from C. forskohlii. Deacetylforskolin activates rat adipocyte adenylyl cyclase (IC50 = 20 µM), inhibits glucose transport in rat adipocyte plasma membranes and exhibits antihypertensive activity .
    Deacetylforskolin
  • HY-W769935
    5-POHSA

    		Free Fatty Acid Receptor Metabolic Disease
    5-POHSA, a fatty acid esters of hydroxy fatty acid (FAHFA), potentiates glucose transport .
    5-POHSA
  • HY-120974
    α-lipoic acid derivative 1

    		GLUT Metabolic Disease
    α-Lipoic Acid Derivative 1 (Compound AN-7) is an α-lipoic acid derivative that enhances glucose transport in skeletal muscle by releasing active α-lipoic acid (LA), significantly improving glucose metabolism. In L6 skeletal muscle cells, α-Lipoic Acid Derivative 1 significantly increases glucose transport rates, approximately 12 times more potent than the parent compound α-lipoic acid (HY-N0492). In a mild diabetic mouse model, 10 mg/kg of α-Lipoic Acid Derivative 1 administered for two weeks significantly reduced blood glucose levels by 39%. α-Lipoic Acid Derivative 1 shows significant potential in research related to glucose metabolism in diabetes .
    α-lipoic acid derivative 1
  • HY-123547
    TLK19781

    		Insulin Receptor Others
    TLK19781 is a non-peptide small molecule insulin receptor activator that increases the content of insulin-stimulated GLUT4 on the cell membrane and enhances the activity of insulin-stimulated glucose transport in cell and animal models of insulin resistance.
    TLK19781
  • HY-101849R
    Fasentin (Standard)

    		Reference Standards GLUT TNF Receptor Apoptosis Cardiovascular Disease Cancer
    Fasentin (Standard) is the analytical standard of Fasentin. This product is intended for research and analytical applications. Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .
    Fasentin (Standard)
  • HY-176253
    Antitrypanosomal agent 26

    		Parasite Infection
    Antitrypanosomal agent 26 (Compound 1) is an allosteric trypanosome alternative oxidase (TAO) inhibitor. Antitrypanosomal agent 26 exhibits potent activity against African animal trypanosomes (e.g., Trypanosoma brucei, etc.) with an IC50 value of 1.3 nM for recombinant TAO. Antitrypanosomal agent 26 blocks the mitochondrial electron transport chain of trypanosomes and inhibits glucose-dependent respiration. Antitrypanosomal agent 26 is promising for research of African animal trypanosomiasis, such as bovine trypanosomiasis .
    Antitrypanosomal agent 26
  • HY-N2024AS2
    Maltose monohydrate-13C

    		Isotope-Labeled Compounds Endogenous Metabolite Glycosidase Metabolic Disease
    Maltose monohydrate- 13C is the 13C labeled isotope of Maltose monohydrate. Maltose monohydrate is a disaccharide composed of two glucose molecules linked together. Maltose monohydrate is an endogenous metabolic product in plants, yeast, or bacteria, and it participates in carbon source storage and metabolism. Maltose monohydrate is a key core metabolite and main transport form in the temporary starch degradation, carbon output, and subsequent sucrose synthesis metabolism of the night chloroplast. In X. dendrorhous, maltose can act as a sugar donor and is converted into isomaltulose by α-glucosidase. Maltose monohydrate can act as a osmotic agent, supporting continuous capillary ultrafiltration and preventing severe metabolic disorders.
    Maltose monohydrate-13C
  • HY-19310
    AMP-579

    		Adenosine Receptor Cardiovascular Disease Metabolic Disease
    AMP-579 is an adenosine receptor agonist that primarily targets adenosine A1 and A2A receptors (with Ki values of 1.7 and 4.5 nM for the A1 receptor in rat brain and adipocytes, and a Ki value of 56 nM for the A2A receptor in rat brain). AMP-579 inhibits lipolysis, restores insulin-dependent glucose transport, and reduces heart rate through the activation of A1 receptors, while it induces vasodilation, particularly in coronary arteries, through the activation of A2A receptors (with an IC50 of 0.3 μM in porcine coronary arterial rings). AMP 579 shows potential for application in cardioprotection and the treatment of acute myocardial infarction .
    AMP-579
  • HY-D3196
    AG2

    		Fluorescent Dye Cancer
    AG2 is a glucose uptake tracer and two-photon fluorescent probe. AG2 is taken up by cells via glucose-specific transport systems, rather than passive diffusion; it preferentially accumulates in cancer cells and colon cancer tissues compared with normal cells and tissues; it mainly localizes to mitochondria, with a small amount also distributed in the cytoplasm and cell membrane. AG2 can be used for colon cancer research .
    AG2
  • HY-182014
    TLC-2716

    		LXR Cardiovascular Disease Metabolic Disease
    TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders .
    TLC-2716
  • HY-179631
    2DG-ODDA

    		Apoptosis Cancer
    2DG-ODDA is a 2-deoxyglucose (2-DG) (HY-13966) derivative with potent antitumor activity. 2DG-ODDA induces apoptosis, and reduces ATP production. 2DG-ODDA is taken up through both fatty acid and glucose transporters and is cleaved by α-Mannosidase (HY-P2950), releases 2DG to inhibit N-glycosylation and disrupt cellular metabolism. 2DG-ODDA inhibits tumor growth in a 4T1 mouse model. 2DG-ODDA can be used for the research of triple-negative breast cancer (TNBC) .
    2DG-ODDA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: